Characterization of pretreatment cachexia through cytokine and nutritional analysis in patients with non-small cell lung carcinoma: the Marato cohort

This prospective study of 52 patients with unresectable locally advanced non-small cell lung cancer reveals that pretreatment cachexia is highly prevalent and significantly associated with specific inflammatory cytokines, nutritional deficits, and body composition changes, thereby identifying novel biomarkers and potential therapeutic targets.

The Gist

The Big Picture: The "Empty Tank" Problem

Imagine a car (the patient) that has a powerful engine (the tumor) running inside it. This engine is so greedy that it starts stealing fuel and parts from the car's own body to keep running. This causes the car to lose weight, lose its paint (fat), and have its chassis weaken (muscle loss). In the medical world, this is called cancer cachexia.

This study looked at 52 drivers (patients) with a specific type of lung cancer (NSCLC) who were about to get a major tune-up (chemotherapy and radiation). The researchers wanted to answer three questions:

1. How many of these drivers were already running on empty before the tune-up started?
2. What does the "dashboard" (blood tests and body scans) look like for those who are running on empty?
3. Are there specific "warning lights" (chemical signals in the blood) that tell us exactly why the car is losing fuel?

The Findings: A Snapshot Before Treatment

1. The Prevalence: More than Half Were Running Low
Before any treatment began, 53% of the patients already met the strict criteria for cachexia. It's like walking into a garage and finding that more than half the cars already have their fuel tanks below the "low fuel" line, even though they haven't started the long journey yet.

2. The Dashboard: What's Different About the "Empty" Cars?
The researchers compared the "empty" cars (cachectic patients) to the "full" cars (non-cachectic patients). They found distinct differences:

• The Fuel Gauge: Cachectic patients ate significantly fewer calories. They were running on a diet that was too low for their needs.
• The Body Scan: These patients had less muscle and less fat. It wasn't just that they weighed less; the quality of their body composition was different. They had less "structural steel" (muscle) and less "insulation" (fat).
• The Engine Noise: The "empty" cars had higher levels of inflammation. Think of this as the engine overheating or the dashboard lights flashing red (high C-Reactive Protein).
• The Driver's Strength: The cachectic patients had weaker handgrips, like a driver whose arms are too weak to steer the wheel firmly.

3. The Mystery of the "Warning Light" (GDF-15)
Scientists have been chasing a specific chemical called GDF-15, hoping it acts like a perfect "Check Engine" light for cachexia.

• The Result: In this study, GDF-15 was high in many patients, and it did correlate with how much weight they had lost.
• The Catch: However, it wasn't a perfect alarm. Many patients who didn't have cachexia also had high GDF-15. It's like a smoke detector that goes off when you burn toast, not just when there's a fire. It wasn't specific enough to diagnose the problem on its own.

4. The Real Culprits: A New List of Suspects
Since GDF-15 wasn't the whole story, the researchers used a high-tech scanner (proteomics) to look at 384 different proteins in the blood. They found a new list of "suspects" that were much more specific to the cachexia problem:

• The Agitators: Proteins like IL-6 and CCL23 were much higher in the "empty" cars. These seem to be the ones actively causing the inflammation and muscle wasting.
• The Confusing Signals: They found AGRP, a chemical that usually tells the body to eat. Surprisingly, it was high in the patients who were not eating. The researchers think this might be the body's desperate, failed attempt to say, "Hey, we need food!" while the tumor ignores the signal.
• The Missing Parts: Some helpful proteins, like RANKL, were lower in the cachectic patients.

What This Means (According to the Paper)

The study concludes that cancer cachexia is a very common, complex syndrome that starts before treatment begins. It's not just about losing weight; it's a specific biological state involving inflammation, low food intake, and a unique chemical signature in the blood.

The most important takeaway is that while we know GDF-15 is involved, it's not the only player. There is a whole "orchestra" of different proteins (like CCL23, IL-6, and AGRP) playing together to cause this condition. Identifying this specific orchestra gives scientists a better map to understand the problem, though the paper notes that we still need to figure out exactly how to silence these specific "noisy" proteins to help the patients.

In short: The study mapped the "terrain" of lung cancer patients before treatment, found that over half were already suffering from a complex metabolic syndrome, and identified a new set of chemical clues that explain why their bodies are wasting away, offering a more detailed picture than just looking at weight loss alone.

Technical Summary

1. Problem Statement

Cancer cachexia is a multifactorial syndrome characterized by involuntary weight loss, skeletal muscle wasting, and adipose tissue depletion, significantly impacting the quality of life and prognosis of patients with Non-Small Cell Lung Carcinoma (NSCLC). Despite its prevalence (affecting 30–45% of NSCLC patients), the syndrome is difficult to assess clinically, and its underlying molecular mechanisms remain incompletely understood.

• Gap in Knowledge: Most existing studies rely on preclinical models or focus on specific cytokines (e.g., GDF-15) without a comprehensive, multidimensional assessment of the cachexia phenotype in a prospective clinical setting.
• Clinical Need: There is a lack of specific biomarkers to guide targeted therapeutic interventions, and current diagnostic criteria (Fearon's) may not fully capture the heterogeneity of body composition changes in patients who are overweight or obese.

2. Methodology

The study employed a prospective, observational, multidisciplinary design involving 52 patients with locally advanced, unresectable NSCLC (Stage IIB–IIIC) recruited between April 2022 and March 2024. All patients were scheduled for concurrent chemoradiotherapy followed by consolidation immunotherapy (durvalumab).

Key Assessment Dimensions:

• Cachexia Definition: Diagnosed using Fearon's consensus criteria (Weight Loss >5% in 6 months, or >2% with BMI <20 kg/m² or sarcopenia). Sarcopenia was defined as the lowest sex-specific tertile of the Skeletal Muscle Index (SMI).
• Body Composition: Quantified via CT scans at the L3 vertebral level using SliceOMatic software to measure Skeletal Muscle Area (SMA), Visceral Adipose Tissue (VAT), and Subcutaneous Adipose Tissue (SAT). Indices were normalized to height squared (SMI, VATI, SATI).
• Nutritional & Functional Status: Assessed via Patient-Generated Subjective Global Assessment (PG-SGA), 24-hour dietary recall (caloric/macronutrient intake), handgrip strength (dynamometry), and gait speed.
• Metabolic & Inflammatory Markers: Blood tests included CRP, albumin, insulin, glucose, HOMA-IR, and the Modified Glasgow Prognostic Score (mGPS).
• Proteomic Profiling: Serum samples were analyzed using the O-link Explore 384 Inflammation I panel to quantify 384 cytokines and proteins. GDF-15 was measured separately via Elecsys® assay.
• Statistical Analysis: Associations were tested using Mann–Whitney U, Chi-square, and Spearman's rank correlation. Survival analysis (OS/PFS) utilized Cox proportional hazards models.

3. Key Contributions

• Multidimensional Phenotyping: This is one of the first studies to integrate body composition (CT-based), detailed nutritional intake, physical function, and high-dimensional proteomics in a single prospective cohort of locally advanced NSCLC patients before treatment initiation.
• Novel Biomarker Discovery: Identification of a specific cytokine signature associated with cachexia beyond the well-known GDF-15 and IL-6, including previously understudied proteins like CCL23, Motilin (MLN), and AGRP.
• Re-evaluation of GDF-15: A critical analysis of GDF-15's utility as a standalone diagnostic marker for pre-treatment cachexia in this specific population.

4. Key Results

Prevalence and Clinical Correlates:

• Prevalence: 53% of patients met Fearon's criteria for cachexia at baseline.
• Associations: Cachexia was significantly associated with:
  • Advanced tumor stage (p < 0.001).
  • Lower SMI, VATI, and SATI (p < 0.005).
  • Elevated CRP and mGPS (p < 0.005).
  • Moderate-to-severe malnutrition (93% of cachectic vs. 5% of non-cachectic; p < 0.001).
  • Reduced caloric intake (1575 vs. 1936 kcal/day; p = 0.007) and lower fat intake.
  • Reduced handgrip strength (p = 0.001).
• Survival: Cachexia was associated with shorter Overall Survival (OS) and Progression-Free Survival (PFS) in univariate analysis, though this significance was attenuated after adjusting for tumor stage and performance status.

Proteomic Findings:

• Differentially Expressed Proteins: 54 proteins were differentially expressed (p < 0.05); 16 remained significant after FDR correction.
• Upregulated in Cachexia:
  • Inflammatory: IL-6, CCL23, CSF1, C1QA (complement factor), PTX3, OSM.
  • Metabolic/Neuropeptides: Motilin (MLN), Agouti-related protein (AGRP), Soluble CD4, CD276.
  • Correlations: CCL23 and IL-6 correlated positively with weight loss and negatively with caloric intake. AGRP (an appetite stimulant) was paradoxically elevated but inversely correlated with adipose tissue, suggesting a compensatory mechanism.
• Downregulated in Cachexia:
  • RANKL (TNFSF11), LRRN1, FLT3LG, Persephin, ENPP5.
  • Correlations: RANKL levels decreased as weight loss increased and caloric intake dropped.

GDF-15 Analysis:

• While GDF-15 levels were elevated in 74% of patients and correlated strongly with percentage of weight loss (r = 0.52, p = 0.00014), it did not significantly differentiate between cachectic and non-cachectic patients (p = 0.08).
• GDF-15 showed no correlation with caloric intake or body composition indices, indicating low specificity for diagnosing cachexia in this cohort despite high sensitivity for weight loss.

5. Significance and Implications

• Clinical Stratification: The study highlights that relying solely on weight loss or BMI is insufficient. A significant portion of cachectic patients were overweight/obese, and some had preserved muscle mass despite meeting weight-loss criteria. Multidimensional profiling is essential for accurate diagnosis.
• Therapeutic Targets: The identification of CCL23, Motilin, and AGRP as novel candidates suggests new pathways for intervention. For instance, the paradoxical elevation of AGRP suggests a complex dysregulation of appetite signaling that could be targeted.
• Limitations of GDF-15: The findings suggest that anti-GDF-15 therapies (e.g., ponsegromab) might need careful patient selection, as GDF-15 elevation alone may not define the cachexia phenotype in all NSCLC patients.
• Future Directions: The study underscores the need for longitudinal monitoring and larger, gender-balanced cohorts to validate these novel biomarkers and refine the definition of cancer cachexia for precision medicine approaches.

In conclusion, this study provides a comprehensive biological and clinical map of pre-treatment cachexia in NSCLC, moving beyond simple weight metrics to identify specific inflammatory and metabolic signatures that could drive future therapeutic strategies.